AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
Source ↗
👁 0
💬 0
Featured at this year’s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and several targeted medicines for lung tumors.
Comments (0)